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Summary
Objective: To outline the best available method of measurement for detecting progression of osteoarthritis (OA) of the hip especially in
therapeutic trials.
Method: A Medline search of articles related to progression of hip OA was performed. A group of experts met over a 1.5-day session to review
available literature and new research. Speciﬁc questions were addressed in order to reach a consensus on measuring progression of OA of
the hip.
Results: Of the available surrogate measures, a single yearly standing or reclined antero-posterior plain radiograph of the pelvis with feet
internally rotated 15e20(, can be evaluated with the use of an atlas for joint space width (JSW, interbone distance). There should be
a minimum JSW upon baseline screening that may be 1 or 2 mm. Digitization of ﬁlms offers a slight reduction in variability of measurements.
Progression of OA can be calculated by measurement of the JSW on paired and blinded ﬁlms. A reduction of R0.5 mm is greater than the
‘minimum perceptible difference’ as well as the variation of most imaging techniques, and represents a clinically relevant and signiﬁcant
reduction in the JSW. Narrowing of the superomedial or superolateral JSW may tend to progress more rapidly than other changes. In clinical
trials, patients who discontinue the study treatment need to be followed after discontinuation, and an imputation strategy which provides
unbiased estimates of both the treatment effect and its variance is an appropriate technique for intent-to-treat analysis.
Conclusion: For the development of new agents intended to prevent, retard, stabilize or reverse the progress of OA of the hip, the radiographic
methodology presently available is adequate to detect changes in hip JSW of OA.
 2004 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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SocietyIntroduction
Osteoarthritis (OA) of the hip is a common and potentially
disabling condition. Indeed, in the surgical prevention of
painful disability it is estimated that annually between 50 and
140 per 100 000 inhabitants of the developed countries
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Received 3 November 2003; revision accepted 4 April 2004.51receive a total hip arthroplasty for OA1. The number of
procedures not only reﬂects the success of the surgical
procedure, but also indicates the failure of non-surgical
regimens to adequately treat and prevent progression of
symptomatic OA.
There is an ongoing effort to change the therapy of OA
from symptomatic to structure (disease) modiﬁcation.
Several agents are being evaluated for their potential to
alter the course of OA. Guidelines for conduct of clinical trials
for structure modiﬁcation of the hip and knee have been
proposed2,3.
More recently, a consensus group summarized the
measurements that would be appropriate for the knee4.
Further guidance for knee OA is expected from the5
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was cosponsored by the National Institutes of Health,
OMERACT (Outcome Measures in Arthritis Clinical Trials),
and OARSI (Osteoarthritis Research Society International).
However, there has been no recent conference address-
ing progression of OA of the hip. Hence, a workshop was
organized with a limited number of experts. Speciﬁc ques-
tions discussed by the panel addressed the methods for
determining structural progression of OA of the hip.
Methods
A Medline search for OA of the hip for the time period of
January 1, 1993 through January 1, 2003 was performed,
with reference to disease progression. The search included
the following keywords: hip osteoarthritis, hip progression,
hip X-ray. Appropriate articles were reviewed and consti-
tuted the basis of the panel discussions.
After reviewing the literature, a group of experts met for
a 1.5-day session. The purpose of the preliminary half-day
meeting was to collate the questions and outline the next
day’s agenda. The agenda for the full-day meeting included
several presentations of published and unpublished data,
with continuous discussion about the questions raised in the
preliminary meeting. Indeed, the questions were presented
at the beginning of the day and reassessed several times
throughout the day.
Listed below are the results of the panel discussion, that
is, a consensus which is based on the best knowledge of
the experts with the support of the available evidence.
For purposes of this review, ‘joint space width’ (JSW) will
refer to interbone distance and ‘mean JSW’ will refer to the
average JSW from the pelvic brim to the medial extreme of
the acetabular roof. The joint space area is deﬁned as the
area of the interbone distance for the area between the
pelvic brim to the medial extremity of the acetabular roof, or
to the medial brim of the articular surface of the acetabular
roof. The reduction in JSW can be rated over time as the
‘rate of narrowing of the JSW.’ To be meaningful, the JSW
narrowing rate should reﬂect the same length of follow-up
for all study subjects, and is often annualized.
Results
BACKGROUND
Guidelines have been developed for the conduct of clinical
trials in OA of the hip2,3. There appears to be two types of
therapeutic trials for OA: (1) pain and/or function, and (2)
structure (disease) modiﬁcation. The medical literature is
replete with trials directed at symptom modiﬁcation. The
concept of structure modiﬁcation is relatively new, and no
agent is universally accepted as being able to alter pro-
gression of OA. Part of the problem in assessing structure
modiﬁcation concerns the use of a validated outcome mea-
sure. Many studies on structure modiﬁcation have been
conducted in animals to determine joint preservation.
Although useful, information from animal models is not
easily transferred to humans. Since access to joint speci-
mens in humans is limited, there is a need for a surrogate
outcome measure that reﬂects joint changes.
MEASURES OF PROGRESSION
Among the surrogates for hip OA structural progression,
several potential candidates could be considered as putative
outcome measures for structure modiﬁcation (Table I).After reviewing the literature, the consensus of the group
of experts was that each of the candidates has potential;
however, at this time only radiography is validated ade-
quately to be regarded and used as a primary endpoint for
change in OA of the hip.
Arthroscopy
Arthroscopy of the hip is not as advanced as arthroscopy
of other joints, such as the knee. Hip arthroscopy is
performed for loose bodies, labral injuries, to identify focal
chondral lesions or for ‘‘clean-out’’ in late stages of Legge
CalveePerthes disease5. Because of the anatomy, only the
periphery and the iliofemoral joint can be examined, the latter
requiring distraction6. However, labral disruptions that can be
detected arthroscopically, may predict progression7.
Bone scanning
Bone scanning can reveal increased localization of
radionuclide in and about the hip related to subchondral
remodeling and synovitis. When OA of the hip is severe
enough, the bone scan may be difﬁcult to separate from
later stages of avascular necrosis of bone. Although there
are some data on bone scanning for hand and knee, the
panel could ﬁnd no study examining bone scanning for
progression of OA of the hip.
Computed tomography
Computed tomography (CT) provides detail about the
subchondral bone with the potential to measure JSW. No
publications could be found that have performed cross-
sectional or longitudinal studies of CT in OA of the hip.
Laboratory markers
Laboratory markers for progression of OA of the hip have
not yet been validated and there is less information for the hip
than for OA of the knee. Of the limited information available
for the hip, C-reactive protein8, cartilage oligomeric matrix
protein (COMP)9, YKL-4010, matrix metalloproteinase-3 and
-911, and tissue inhibitor of metalloproteinase-1 (TIMP-1)12
show the greatest promise. In a 1-year longitudinal study,
COMP (but not bone sialoprotein) correlated with the yearly
narrowing of the mean JSW13. These data were not adjusted
for ethnicity or sex14. In another 1-year longitudinal study,
TIMP-1 at over 600 ng/ml (but not hyaluronic acid serum
levels) were predictive of narrowing of the JSW12. Both of the
longitudinal studies used the radiograph as their reference
for OA progression. Some of the studies attempted to detect
Table I
Potential measures of progression of osteoarthritis
Structural
 Arthroscopy
 Computed tomography
 Magnetic resonance imaging
 Radiography
 Ultrasound
Process
 Bone scanning
 Laboratory markers
Other
 Time to joint replacement
 Patient-relevant symptoms and function*
*Not discussed in the text.
517Osteoarthritis and Cartilage Vol. 12, No. 7subjects with rapidly destructive changes or osteonecrosis of
the hip15,16. Additional support for laboratory markers stems
from a 3-year structure-modifying trial, suggesting value to
combined measurement of serum C-terminal crosslinking
telopeptide of collagen type II (CTX II) and hyaluronan17.
There are suggestions that genetic markers may help
detect those more prone to incident disease, and hence
disease progression. A genetic inﬂuence on OA of the hip is
supported by family studies18. In a study on 392 patients with
OA of the hip, compared to 604 siblings and 1718 controls,
the age-adjusted odds ratio in siblings was 6.4 for deﬁnite
OA of the hip19. In an examination of 135 monozygotic and
277 dizygotic O50 year old female twins using a modiﬁed
Kellgren & Lawrence grading and individual features, there
was a 58% heritability of OA and a 64% heritability for
narrowing of the JSW20. There appeared to be more con-
cordance with severe disease among monozygotic female
twins than among those with lesser severity of OA. For hip
speciﬁc OA, there was evidence that the COL9A1 may be a
susceptible locus for hip OA in women, with a likelihood of
odds (LOD) score of 2.33 (PZ0:00053)21. There was
weaker evidence for a linkage with COLII9A2.
Magnetic resonance imaging (MRI)
To date there has been no published quantitation of hip
cartilage by MRI. There is limited information on the ideal
imaging techniques. It appears that MRI on a coronal
projection reﬂects primarily femoro-iliacal cartilage thick-
ness, not other areas of the hip such as femoro-pubic and
femoro-ischial cartilage. In limited studies, cartilage thick-
ness was examined in three patients with OA22. Three-
dimensional reconstruction of cartilage failed in one of the
cases, due to narrowing of the JSW. The MRI judged the
normal cartilage thickness of the femoral head to be 1.1 mm
lateral, 1.3 mm medial and 2.8 mm around the ligamentum
teres. No data were presented on the acetabular cartilage.
MRI was felt to be of advantage in rapidly destructive OA of
the hip, but the studies apparently only studied patients at
late stages of disease23,24. However, for clinical purposes,
MRI in the sagittal plane can detect abnormalities of cartilage
whereas the standard radiograph may not25.
Time to hip surgery
Comparison of survival curves between treatment groups
from study entry for time to hip replacement surgery is
a measurable surrogate, and attractive as an endpoint for its
simplicity. Objections to using time to surgery as an endpoint
include the variation among countries on the frequency of
joint replacement surgery, variations in access, and variable
clinical criteria for hip replacement being used1.
Many factors inﬂuence the decision for hip surgery, such
as: symptoms; change in X-ray; patient’s needs, require-
ments and willingness; co-morbidities, waiting lists, social;
economic; societal; insurance coverage; etc. These criteria
are difﬁcult to standardize since there is considerable
variation among surgeons as to when joint replacement
becomes indicated and unfortunately, there are no gener-
ally accepted guidelines for hip joint replacement surgery
other than joint pain and an abnormal radiograph.
Hence, it appears necessary to determine at what point
joint replacement would be appropriate. Lequesne et al.
developed the algofunctional index for such a purpose26.
Although not validated for that purpose, a score in the range
of 10e14 out of a maximum of 24 was considered as an
indication for surgery.A composite index has been proposed that includes
symptom, structural and therapeutic variables27. Further
testing of the score suggests that it may be used to
determine which patients should not be referred for joint
replacement28. The same group suggested changes in
JSW to be the best predictor of the need for hip arthroplasty;
hence, time to joint replacement could be a surrogate for
narrowing of the JSW; it also suggested that a reduction in
JSW of 0.2 mm or more (15%) in a year, or 0.4 mm (20%) in
2 years has acceptable sensitivity and speciﬁcity for
decision on joint replacement surgery29. Explicit criteria
have also been suggested, but to date there has been no
further validation of the utility of these criteria30.
Ultrasound
The panel could ﬁnd no trials examining ultrasound for
assessment of OA progression of the hip. It is uncertain if
the methodology has become sensitive enough to assess
thickness or volume of articular cartilage.
Radiographic technique and processing
Hip radiographs can be obtained in the standing or
reclined position31. In a study of 30 patients, weight-bearing
radiographs of the hip were narrower than reclined views
only for those with a maximum JSW of !2.5 mm; this
suggests weight-bearing radiographs may be preferable for
prospective structure-modifying trials32. However, for the
consensus among the group of experts was that there may
not be any signiﬁcant advantage to standing, as radio-
graphs obtained while reclined in normals appear similar
(Table II). However, since normal hips are not OA hips, the
choice remains between standing and supine positions. If
the radiograph is obtained standing, the feet should be
internally rotated 15e20(, and a foot map should be used.
Variations in foot rotation increases the variability in JSW
measurements33. If the radiograph is obtained while
reclined, there should be a slight medial stress (i.e., internal
rotation or inversion of the foot) to press the femoral head
toward the acetabulum. The X-ray beam should be
centered to the upper pole of the symphysis pubis and
both hips included in a single antero-posterior 14!17 inch
(30!40 cm) ﬁlm. The distance, time, millivolts, and milli-
amperes should be carefully recorded. Special views and
separate radiographs for each hip have been suggested to
improve interpretation of change. They can be used, but do
not seem to provide signiﬁcant advantages over the single
antero-posterior view and present special problems in
repositioning.
An oblique view of the hip was described by Lequesne
and Laredo34. The Lequesne false proﬁle of the hip was
compared with the standard antero-posterior radiographs in
Table II
Hip JSW on pelvic radiographs: comparison of standing with supine
technique. Ninety-two consecutive patients due for colon radiogra-
phy were included, and a standing AP view added to the standard
protocol. Both radiographs were taken with 100 cm film-focus
distance. One hundred and seventy-three hips were available for
comparison
N Range Min Max MeanG SD
Standing (mm) 173 4.5 1.5 6 3.8G 0.8
Supine (mm) 173 4.5 1.5 6 3.6G 0.7
mm, millimeters; Min, minimum; Max, maximum; SD, standard
deviation.Data from Ingvarsson et al.79
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of JSW in about one-third of the patients suggesting that the
two views may be of beneﬁt in prospective trials; however,
this has not been tested and veriﬁed to date.
In summary, antero-posterior radiographs of the pelvis
that includes both hips with feet rotated in 15e20( should
be obtained utilizing a foot map with slight advantage of
weight-bearing over reclined position in more severely
narrowed hips.
Measurements
Once obtained, ﬁlms should be forwarded to a central
location for reading. There should be an initial reading of the
screening ﬁlm for conﬁrmation of eligibility to enter the study
(i.e., conﬁrmation of diagnosis and stage of OA). For
purposes of classiﬁcation, the use of an atlas provides a set
of standards36e39. Once selected, the same atlas should be
used throughout the trial40. The reading of individual fea-
tures is more sensitive to change than the global Kellgren &
Lawrence score40,41.
In summary, studies should include central readings of
radiographs using individual radiographic features graded
from a published atlas. Consensus is that radiographs
should be obtained yearly, although there have been no
studies to examine the time needed to detect minimal
change. This recommendation is based on published trials,
discussed below. Obtaining annual radiographs is felt to
minimize loss of information with intent-to-treat analysis of
discontinuations. It is to be noted that by intent-to-treat
analysis, we mean that all patients receiving at least one
therapy are included in the ﬁnal analysis. If statistical
imputation strategies are to be used for missing data, then
these strategies should be speciﬁed in the statistics plan of
the protocol.
Reading of images
A coordinating center collates and codes the radiographs.
The code should be alpha-numeric, and should blind the
reader to the demographic information. The panel of experts
felt that all reading systems contain some bias. It may be that
the least bias would occur when the reader(s) gathers and
reads each subject’s sets of ﬁlms together, without knowl-
edge of their sequence. For rheumatoid arthritis, there has
been a recommendation that the sequence of reading
radiographs be known to the reader42. The expert group’s
consensus was that sequence should be unknown to the
reader(s), since there is risk for greater bias in OA, and
progression is not inevitable43.
While reading, the assessor should ‘‘break’’ from reading
every hour to prevent fatigue. Readings should include
testeretest and a calculation of inter- and intra-observer
variability when there is more than one reader. The reader
should be seated and the viewing box should be horizontal44.
In relation to the number of readers, in a study of 118 twin
pairs, it was determined that there should be a minimum of
one skilled reader of the radiographs45. The conclusion was
that for less experienced assessors, two may be needed.
Indeed, most published trials have included one highly
skilled reader. In contrast, in an examination of 40 sets of hip
radiographs, read by eight skilled readers, it was found that
the most consistent results occurred with three readers46.
For OA of the hip, four reading techniques for a single
reader were compared in a study of 104 patients with two
radiographs separated by 3 years47. Abnormal images
were more frequently detected by Kellgren & Lawrence
grading with paired readings and landmarks identiﬁed onthe ﬁlm. In a study that compared two different grading
methods, the overall number of OA hips was the same, but
they overlapped only some of the same individuals, without
demonstrating superiority of one of the methods48.
In summary, a central reading center should use blinded
radiographs to patient and sequence. A very experienced
reader is acceptable, but readings may be more consistent
with up to three readers. Consistency of interpretation
needs to be established for all trials with rereading of
radiographs.
What and how to measure
Of the possible anatomic features of the hip (Table III),
measurement of the JSW at the narrowest point appears
most consistent when examining progression39. There are
several methodologies for determining JSW that have been
proposed (Table IV).
The distance between bony plates correlates with the
articular cartilage thickness, and can be read with a grad-
uated magnifying glass as described by Lequesne49,50.
Joint space surface area and mean JSW were measured
using a computer program that analyzed digitalized frontal
weight-bearing pelvic radiographs51. Three separate ﬁlms
for each of 20 hips were reviewed ﬁve times by two ob-
servers. The inter-observer coefﬁcient of variation for joint
space area and mean JSW was 5% and 4%, respectively.
The correlation coefﬁcient with the Lequesne magnifying
eyepiece technique was r ¼ 0:89, suggesting computerized
readings may be useful in clinical trials.
Alternative digitizing programs have been developed that
automatically ﬁnd the articular margins of the hip to produce
measurements of the minimum JSW and joint space area52.
Table III
Radiographic features of osteoarthritis of the hip
Osteophytes
Superior femoral
Inferior femoral
Inferior acetabular
Superior acetabular (difﬁcult to interpret)
Joint space narrowing
Superolateral
Superior
Superomedial
Subchondral sclerosis
Femoral
Acetabular
Subchondral cysts
Femoral
Acetabular
Buttressing
Table IV
Methods of measuring JSW
 General reading
B Kellgren & Lawrence grade
B Scale (e.g., 0Z normal; 3Z complete loss of joint space)
 Caliper
B Hand held
B Digitized
 Magnifying glass
B mm scale in eyepiece
 Digitized image
B Assessor-marked landmarks
B Computer-assisted landmarks
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(discussed below) were measured both by using the
eyepiece and by computerized analysis of hip ﬁlm radio-
graphs that were digitized49,53. Both methods were judged
efﬁcient, with the computerized technique showing less
variation.
An alternative to the measurement of the JSW with
a graduated eyepiece is the use of an electronic caliper.
This was tested and found efﬁcient in 100 hip radiographs,
including 50 patients with OA54.
In a study comparing JSW on ﬁlms read manually or
digitized, the smallest detectable difference of JSW was
0.78 mm when measured manually and 0.67 mm when
measured by computer, for a non-statistical difference55.
The smallest detectable difference was less (0.47 mm) by
computer when calculating the average JSW. The smallest
detectable differencewas 0.5 mm in theECHODIAHstudy53.
At this time, there are no prospective studies examining
images that were obtained by the new digitized techniques
that no longer use ﬁlm images.
In summary, sequential measurements of JSW by
interbone distance is the recommended method for detect-
ing progression. Measurement of JSW can be performed
with a calibrated eyepiece, an electronic caliper or by
computer. Consistency of interpretation needs to be
established for any method used.
The radiographic JSW
Normal
The superior aspect of the normal hip demonstrates
a JSW of 2e5 mm. In a study of 78 normal hip radiographs,
there was no difference in JSW between right and left
sides, but women had a narrower mean JSW than men
(women: 6:4G1:0mm vs men: 7:2G1:0mm; meanG SD;
P ¼ 0:001)49. Another review of 118 normal radiographs
measured the average JSW to be 3:6G0:6mm in the right or
left hip, without an age-related decline in JSW56. However,
there was an age-related decline in JSW in another study,
even when OA of the hip was excluded57. Although the JSW
of hips of women were narrower than men, this difference
was not signiﬁcant when adjusting for height57.
In summary, most normal hip radiographs are between 2
and 5 mm at its narrowest point.
Abnormal
The prevalence of hip OA in Iceland has been assessed48.
Reclined pelvic scout X-ray ﬁlms (N ¼ 1517) obtained prior
to double contrast barium enemas were reviewed for the
presence of hip OA, using a minimal JSW of 2.5 mm or less
as a criterion for hip OA. The overall prevalence was 11%,
rising each decade to 35% in those R85 years old. In
a follow-up study, 294 hips were randomly selected from
3002 radiographs. Intra- and inter-observer reliability was
examined57. Minimum hip JSW was measured with a milli-
meter ruler and global assessment made with the use of an
atlas (Kellgren & Lawrence 2e4). Only 166 (66%) were
diagnosed as OA by both systems. Inter- and intra-observer
reliability was greater with JSW measurement than with
global assessment. The use of a qualitative ‘‘greater or
lesser’’ JSW was even less consistent utilizing Kellgren &
Lawrence readings.
In summary, most studies reliably use hip JSW to assist
in the diagnosis of OA.
Range of JSW for inclusion in a trial
In a measurement of the narrowest point, OA was
considered when the hip JSW was %2.558 or %3 mm59.It may be that structure preservation cannot be achieved
when there has been a loss of cartilage beyond a critical
thickness. Although that thickness is not known, it appears
that a minimum JSW is needed. The consensus of the group
was that a minimum joint space of 2 mm would be ideal.
However, because of recruitment problems, a lesser joint
space may be considered, perhaps down to 1 mm. Hence,
measurement of disease progression is possible. A hip JSW
of less than 2 mm appears to be near end-stage disease and
should not be included in clinical trials of structure modiﬁ-
cation. However, although 2.5 mm may be a relevant lower
limit for inclusion in a structure-modifying trial, 1.5 mm
correlated better with clinical symptoms39.
On the other hand, if the JSW is over 5 mm, although
there may be some degree of OA there is probably going to
be slow progression of the disease. The exception might be
if the JSW is narrower than that of the contralateral hip by at
least 0.5 mm (note: this value is empiric and not tested).
In summary, the experts agreed that at this time, the best
radiographic reﬂection of progressive joint disease is the
change in JSW, more accurately described as interbone
distance. The measurements should be taken at the
narrowest point on an antero-posterior radiograph, and that
same point measured in all ﬁlms (minimum JSW). The
minimum JSW at the initiation of a study should be at least
2.0 mm with a Kellgren & Lawrence of at least grade 3.
Progression
The actual pattern of loss of JSW in the population is not
known. In a study of 463 patients with OA of the hip, the
average JSW decreased from 2:2G0:8mm to 1:7G1:0mm
after 2 years60. In an editorial, Lequesne reported rates
of progression as between 0.22 and 0.30 mm/year from
three studies61.
A reduction in JSW can also be expressed as loss of
mean JSW62. A reduction of 0:43G0:43mm yearly might be
expected, when using a computerized technique. Note the
wide variation of the measurement.
It has also been proposed that a reduction in JSW can be
expressed as rate of narrowing of the JSW (JSN, JSW
narrowing rate), often annualized. For example, for mea-
surement made at two time points, a person’s annual rate of
JSN equals the difference from the initial to the ﬁnal
measurement divided by the time between measurements;
it is then either scaled up or down to reﬂect an annualized
rate. However, as discussed in the Biostatistics section
below, there is little data to support loss of JSW over time as
being linear rather than episodic. Hence, this strategy is
problematic.
Another method is to compare KaplaneMeier curves for
‘‘number of days since baseline without progressing more
than a clinically and statistically meaningful amount’’ (e.g.,
0.5 mm)3. As discussed in the Biostatistics section below,
this is the recommended method for the primary compar-
ison of JSN between treatment groups when missing data
are ignored.
In summary, the temporal pattern of rate of loss of JSW in
OA of the hip is unknown. As above, annual radiographs
are recommended. Outcomes of KaplaneMeier curves
should be used for the primary comparison between groups
when missing data are ignored.
How can those at risk for future progression be selected.
At present, there is no single anatomic feature or set of
features that will efﬁciently predict progression or rapid
progression of OA of the hip.
In a study of 272 hips with OA, 80% were eccentric and
20% were concentric63. The eccentric femoral heads
520 R. D. Altman et al.: Progression of hip osteoarthritismigrated superolaterally or superomedially. This group
underwent total joint replacement about 4 years after the
onset of symptoms. Concentric femoral heads migrated
medially, causing progressive thinning of the medial wall of
the acetabulum, with a slower progression.
In a study of 1578 hips with OA, the distribution of change
was superolateral 59%, medial 26%, and global 15%64.
Approximately 20% were bilateral and 55% were women.
In a study of 70 hip joints, superomedial or concentric
(medial) migration of the femoral head was most sensitive
to change50.
In summary, studies are unclear as to whether super-
omedial or superolateral hip OA disease are more likely to
progress. There are no published studies demonstrating
that either demographic or clinical measures at the baseline
of a study can predict progression.
What represents progression. Radiographic features
have been examined for their ability to reﬂect progression.
In a prospective study of 463 patients with OA of the hip by
American College of Rheumatology criteria, several param-
eters including osteophytes, osteosclerosis, subchondral
cysts, femoral head migration, Kellgren & Lawrence grade,
subjective change in JSW and JSW in mm were assessed
for progression60. Progression was deﬁned as a 0.5 mm
reduction in JSW using a magnifying glass. Wide distribu-
tion of loss of JSW, subchondral bone production, and
severity of loss of JSW were predictive of progression.
‘The minimum clinically important difference’ for detecting
change of JSW in radiographic progression of OA of the hip
was determined to be 0.4 mm; this was determined in
a study of 298 patients followed for 3 years65. The mean
loss of JSW for individuals was 0:63G0:74mm.
From a mathematical perspective, the mean JSW was felt
to be more sensitive to change than minimum JSW in
a retrospective review of 69 digitized images of the hip with
a decrease of 0:43G0:43mm per year62.
Loss of JSW was determined in the contralateral hip of
a cohort of 99 patients postoperative from total hip
replacement surgery66. Within 20 months, an initial median
JSW of 3.48 mm declined at a rate of 0.10 mm/year. The
authors determined that 15% of the hips had an accelerated
decline of O0.2 mm/year. They could not identify an asso-
ciated feature that would predict the more rapid progression.
In a similar study of 61 patients followed for 81 months, the
mean JSW narrowed 0:43G0:43mm=year67.
Progression was felt to be deﬁned as R0.6 mm/year in
a 1-year study of 30 patients68. Predictors of progression on
a larger cohort were felt to be: JSW of%2 mm (relative risk,
RR 2.11), superolateral migration of the femoral head (RR
4.25), women (RR 2.51), Lequesne functional index O10
(RR 2.60), and age O65 years old (RR 1.90).
In summary, progression of R0.5 mm in JSW at any hip
site appears clinically relevant. For minimum JSW, this
value represents the minimally perceptible difference: it
takes into account error in reading and variation in imaging
technique (e.g., positioning).
THERAPEUTIC TRIALS (LESSONS LEARNED)
Rejholec studied the effects of an intramuscular glycos-
aminoglycan polysulfuric acid complex on 112 patients with
OA of the hip using a matched pair design for the placebo
group69. After 10 years of therapy, there were 83 pairs
available for evaluation. X-rays were graded by the Kellgren
& Lawrence system. The grade of severity of the treated
group was less than their matched pair control group,whereas they were the same at baseline. Other measures,
including mobility, climbing a 15-step staircase, anti-in-
ﬂammatory drug consumption, development of OA in the
contralateral hip, the number receiving total hip replace-
ment, and other secondary measures statistically favored
the treated group. JSW was measured in 35 pairs after 16-
year follow-up with a 47.5% reduction in JSW for the treated
group vs a 74.5% reduction in JSW in the matched pair
placebo group. Radiographs were obtained in the standing
position. The report did not specify whether the radiographs
were obtained or read centrally, or how reproducible the
radiographs were. There was no indication of blinding of
radiographs or the skill of the reader or readers. There was
no testeretest reported. Most signiﬁcantly, the radiographs
were not available for re-examination for validation of the
results.
Pavelka et al. re-studied the intramuscular glycosamino-
glycan polysulfuric acid complex on 400 patients with OA of
the hip or knee over a 5-year period70. Radiographs were
obtained yearly in the standing position by a single technician
with one X-ray machine, visually matching the follow-up
radiographs to the baseline. The radiographic JSW was
measured at the narrowest point using the Lequesne
technique with an eyepiece that contained a calibrated mm
scale49. Films were paired by patient, but blinded as to
sequence.Of the 117 patients withOAof the hip, overall JSW
decreased over the 5 years by 0:21G0:8mm (meanG SD)
and 0:22G0:8mm for the treated and control groups
(P ¼ 0:53). The potential of patient selection bias was
suggested by subset analysis: if one selected out those with
an initial Kellgren & Lawrence grade R2e4 and a JSW of
R1 mm, the treated group had a trend toward less JSW
narrowing despite the small numbers of patients in theses
cohorts (treated, N ¼ 25, 0.23 mm; placebo, N ¼ 21,
0.52 mm;P ¼ 0:11). There is concern about such selection
bias: patients were included that did not progress, potentially
hiding a beneﬁcial effect of the treatment. In contrast to the
prior study, radiographs are still available for re-examination.
Dougados et al. performed a 3-year study of orally
administered diacerein in a cohort of 507 patients with OA
of the hip by American College of Rheumatology (ACR)
criteria53. Patients had weight-bearing hip radiographs
obtained at baseline and yearly thereafter. Minimum JSW
wasmeasured by a central reader, unaware of the sequence
of radiographs or treatment. There were four primary efﬁcacy
variables: reduction of JSW ofR0.5 mm in the intent-to-treat
population; reduction of JSW of R0.5 mm in the patients
completing the study (completers); mean JSW change in the
intent-to-treat population; mean JSW change in the com-
pleters (Table V). The pitfalls of an intent-to-treat analysis
Table V
Effect of diacerein on hip joint minimum JSW in a 3-year placebo-
controlled OA study (ECHODIAH)
Outcome Diacerein Placebo P value
Patients with R0.5 mm JSW loss (number (percent)):
Intent-to-treat 112 (51%) 136 (60%) 0.036
Completer 62 (47%) 86 (62%) 0.007
Mean JSW loss, in mm (meanGSD):
Intent-to-treat 0.39G 0.81 0.39G 0.75 NS
Completer 0.18G 0.25 0.23G 0.23 0.042
Populations: intent-to-treat: 446 patients (diacereinZ 221;
placeboZ 225); completer: 269 patients (diacereinZ 131;
placeboZ 138). NSZ not signiﬁcant.
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illustrated and discussed in this study, that being the only
primary outcome that was not statistically different between
study groups (see Biostatistics section below).
SPECIAL CLINICAL POPULATIONS
The etiology of idiopathic OA of the hip isdby deﬁni-
tiondnot known, but it is suspected that the risk factors for
different subsets of the population are different71. Studies
may wish to target special populations because of pattern of
joint disease or more consistent predictability of progression.
There appears to be a relatively small subset of patients
with OA of the hip who have rapidly progressive hip OA.
Lequesne has empirically deﬁned rapid progression as
a loss of JSW of O2 mm/year61. This progression occurs
over a period of months, rather than years. It would be
clinically relevant to detect this group: early detection would
allow for more close observation and potentially separate
therapeutic protocols. In a study of 136 patients referred for
joint replacement, rapid radiographic progression was more
commonly associated with superior migration or an atrophic
bone response72. In a study of 61 patients over 81 months,
rapid progressive loss of JSW seemed to relate to older age
and the absence of osteophytes67. In contrast, no pro-
gression was noted with indeterminate, medial or axial
migration, protrusion or mild OA. These criteria for rapid
progression have not yet been validated in prospective
trials.
The relation of obesity to hip OA is less clear than for the
knee73,74. However, there may be a relationship between
obesity and progression as suggested by an increase in the
risk of total joint replacement from the Nurses’ Health
study75. Of the 568 women who reported total hip re-
placement, those with a body mass index (BMI) ofR35 kg/
m2 had a relative risk of 2.6 over the reference population
(with a BMI !22 kg/m2). The relative risk for eventual hip
replacement was 5.2 if the BMI was R35 kg/m2 when the
nurses were aged 18 years.
BIOSTATISTICS
With current radiographic techniques, structure-modifying
trials for OA of the hip will need to be of 2 or more years’
duration. For various reasons, long duration trials are likely
to yield a signiﬁcant percent of subjects not completing the
trial. This presents some statistical challenges, particularly
related to the primary intent-to-treat analysis, wherein all
patients randomized to treatment or control are included in
the comparison of groups.
Two methods are traditionally employed to compare the
progression of a treatment group to a control group: (1) the
comparison between groups of the mean of changes in
JSW from study entry to the end of the study; (2) the
comparison between groups of the proportion of patients
developing JSN (with how much loss of JSW is considered
relevant pre-speciﬁed in the protocoldmany have sug-
gested a loss ofR0.5 mm of JSW to be signiﬁcant). Anyone
achieving a 0.5 mm reduction in JSW at any time in the
protocol would thus be considered a therapeutic failure.
A third option is to use mean values for the treatment
groups of each subject’s percent reduction of JSW from
baseline. In that circumstance, one could empirically set
a difference of 25% or 50% reduction from baseline in JSW
between treated and control groups as being a relevant
outcome.Yet a fourth option is to compare the mean values of the
treatment and control group of patients’ annualized JSN rate.
The difference in means is usually statistically assessed
with a two-sample t-test, and the difference in proportions
with a chi-square test.
Any of the four above methods of deﬁning outcomes to
compare groups can provide valid statistical inferenceswhile
ignoring the missing data. Validity is based on the subjects in
the study for the same length of follow-up, the drop-out rate is
low and occurs for the same reasons across treatment
groups. With the above outcomes, biased conclusions are
likely to result when large amounts of missing data are
present, especially regarding early discontinuations. If one of
these methods is employed, then an intent-to-treat analysis
requires missing data be replaced with ‘‘imputed’’ values.
How the imputations are made can greatly inﬂuence study
conclusions.
For example, in one of the several strategies for statistical
analysis of results used in a recent study53, the ‘‘missing data
strategy’’ replaced all missing data after a subject discon-
tinued treatment with his or her last JSW measurement.
Since the pattern of JSW loss is not simply constant (i.e.,
unchanging over time), early discontinuations led to distorted
results with use of this strategy. Additionally, such a ﬁlled in
data set with a subject’s missing data imputed to equal his or
her last JSW measurement, artiﬁcially reduces variability
between ‘‘observations’’ and gives the analyst ‘‘sample’’
sizes larger than reality. Both reduced variability and
increased sample sizes contribute to smaller than entitled
to standard errors of outcomes, and may lead to optimisti-
cally small P-values and biased conclusions.
For the four outcomes discussed above, a more de-
fensible missing data strategy is based on introducing
multiple probabilistically plausible imputations of the missing
responses. Each set of imputations results in a complete
data set. Under mild assumptions76, the imputations are
unbiased. From the multiple imputations, one obtains esti-
mates of study outcomes and of their uncertainty, allowing
valid statistical inferences to be made on an intent-to-treat
basis77,78. The multiple imputation strategy employed
should use all of the repeated radiographic data available
on patients.
The comparison of the KaplaneMeier curves between
treatment and control groups for ‘‘number of days since
baseline without progressing more than 0.5 mm’’ is a statis-
tically valid intent-to-treat method when the missing data are
ignored. This approach provides a method for dealing with
varying durations of follow-up to achieve the threshold value
of JSN and appropriately deals with cases dropping out of
the study before the threshold value occurs (‘‘censored
data’’) as shown in the diacerein study53. Statistical
comparisons of the KaplaneMeier curves are most often
based on the log-rank test53.
Postscript
Measuring the progression of OA of the hip presents
challenges. Assuredly, newer techniques will be developed
that will more accurately measure the hip as a joint and not
just the area normally occupied by articular cartilage.
However, the new methods will need validation, and vali-
dation takes time. As products are developed that have the
potential to alter the course of OA of the hip, we must test
them with the best methods available. The consensus group
feels that the information synthesized above summarizes the
state-of-the-art in measuring progressive OA of the hip.
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